Clinical Trials Browser

Prostatic Neoplasms

NCT04557059 2026-03-13

PRIMORDIUM

Phase 3 Active not recruiting

693 enrolled

Genitourinary

Prostatic Neoplasms

NCT04720157 2026-03-11

PSMAddition

Phase 3 Active not recruiting

1,145 enrolled

Genitourinary

Prostatic Neoplasms

NCT04821622 2026-03-11

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Phase 3 Active not recruiting

599 enrolled

Genitourinary

Prostatic Neoplasms

NCT05154162 2026-03-03

PRIMARY2

Phase 3 Active not recruiting

660 enrolled

Genitourinary

Neoplasms, Prostatic Neoplasms

NCT03574571 2026-02-27

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Phase 3 Active not recruiting

732 enrolled

Genitourinary

Prostatic Neoplasms

NCT04689828 2026-02-20

PSMAfore

Phase 3 Active not recruiting

469 enrolled 11 charts 1 FDA

Genitourinary

Prostatic Neoplasms

NCT02257736 2026-02-13

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Phase 3 Active not recruiting

982 enrolled 15 charts

Genitourinary

Prostatic Neoplasms

NCT02531516 2026-02-13

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

Phase 3 Active not recruiting

1,503 enrolled

Genitourinary

Prostatic Neoplasms

NCT04455750 2026-02-05

CASPAR

Phase 3 Active not recruiting

61 enrolled

Genitourinary

Prostatic Neoplasms

NCT01946204 2026-02-02

SPARTAN

Phase 3 Active not recruiting

1,207 enrolled 15 charts 1 FDA

Genitourinary

Prostatic Neoplasms

NCT02489318 2026-02-02

TITAN

Phase 3 Active not recruiting

1,052 enrolled 13 charts 1 FDA

Genitourinary

Prostatic Neoplasms

NCT04493853 2026-01-20

CAPItello-281

Phase 3 Active not recruiting

1,012 enrolled

Genitourinary

Prostatic Neoplasms

NCT03767244 2026-01-16

PROTEUS

Phase 3 Active not recruiting

2,517 enrolled

Genitourinary

Prostatic Neoplasms

NCT04513717 2026-01-14

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Phase 3 Active not recruiting

2,753 enrolled

Genitourinary

Prostatic Neoplasms

NCT04647526 2026-01-13

SPLASH

Phase 3 Active not recruiting

455 enrolled 18 charts

Genitourinary

Prostatic Neoplasms

NCT02051218 2025-12-30

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

Phase 3 Active not recruiting

1,380 enrolled

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT04446117 2025-12-18

CONTACT-02

Phase 3 Active not recruiting

575 enrolled 13 charts

Genitourinary

Prostatic Neoplasms

NCT03987386 2025-11-12

Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer

Phase 3 Active not recruiting

186 enrolled

Genitourinary

Prostatic Neoplasms

NCT02194842 2025-09-19

PEACE III

Phase 3 Active not recruiting

446 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT01230866 2025-09-04

Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer

Phase 3 Active not recruiting

150 enrolled

Genitourinary

Prostatic Neoplasms

NCT05336786 2025-09-04

Prostate Cancer Diagnosis by Multiparametric Ultrasound (Wholemount)

Phase 3 Active not recruiting

70 enrolled

Genitourinary

Prostatic Neoplasms

NCT05204927 2025-07-31

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

Phase 3 Active not recruiting

439 enrolled

Genitourinary

Prostatic Neoplasms

NCT04181203 2025-07-30

CARLHA-2

Phase 3 Active not recruiting

490 enrolled

Genitourinary

Prostatic Neoplasms

NCT03834493 2025-07-18

KEYNOTE-641

Phase 3 Active not recruiting

1,244 enrolled 21 charts

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT02319837 2025-07-08

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

Phase 3 Active not recruiting

1,068 enrolled 20 charts 1 FDA

Genitourinary

Prostatic Neoplasms

NCT05288166 2025-06-27

CYCLONE 3

Phase 3 Active not recruiting

925 enrolled 12 charts

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Urogenital Neoplasms

NCT02804815 2025-06-10

Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours

Phase 3 Active not recruiting

11,000 enrolled

BreastGastrointestinalGenitourinary

Breast Neoplasms, Neoplasms, Prostatic Neoplasms, Recurrence, Colorectal Neoplasms

NCT02446444 2025-05-30

ENZARAD

Phase 3 Active not recruiting

802 enrolled

Genitourinary

Prostatic Neoplasms

NCT03582774 2025-05-13

PSMA SRT

Phase 3 Active not recruiting

193 enrolled

Genitourinary

Prostatic Neoplasms

NCT00567580 2025-05-09

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

Phase 3 Active not recruiting

1,792 enrolled 27 charts

Genitourinary

Prostatic Neoplasms

NCT05678322 2025-04-23

Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy

Phase 3 Active not recruiting

26 enrolled

Genitourinary

Prostatic Neoplasms

NCT02692105 2025-03-13

Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer

Phase 3 Active not recruiting

60 enrolled

Genitourinary

Prostatic Neoplasms

NCT04557501 2025-03-13

PATRON

Phase 3 Active not recruiting

800 enrolled

Genitourinary

Prostatic Neoplasms

NCT05004285 2025-03-12

Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis

Phase 3 Active not recruiting

398 enrolled

Genitourinary

Prostatic Neoplasms

NCT05936658 2025-03-12

[18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer

Phase 3 Active not recruiting

138 enrolled

Genitourinary

Prostatic Neoplasms

NCT02446405 2025-02-06

ENZAMET

Phase 3 Active not recruiting

1,125 enrolled

Genitourinary

Prostatic Neoplasms

NCT00223171 2025-01-27

PCS IV

Phase 3 Active not recruiting

630 enrolled

Genitourinary

Prostatic Neoplasms

NCT05348577 2025-01-27

CAPItello280

Phase 3 Active not recruiting

1,035 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT02303327 2024-12-09

Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients

Phase 3 Active not recruiting

307 enrolled

Genitourinary

Prostatic Neoplasms

NCT01444820 2024-12-04

Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate

Phase 3 Active not recruiting

329 enrolled

Genitourinary

Prostatic Neoplasms

NCT01957436 2024-11-12

PEACE1

Phase 3 Active not recruiting

1,173 enrolled

Genitourinary

Neoplasms, Prostatic Neoplasms

NCT02799706 2024-11-05

PEGASUS

Phase 3 Active not recruiting

885 enrolled

Genitourinary

Prostatic Neoplasms

NCT05622162 2024-05-22

MIP7

Phase 3 Active not recruiting

106 enrolled

Genitourinary

Prostatic Neoplasms

NCT01584258 2024-01-19

PACE

Phase 3 Active not recruiting

2,205 enrolled

Genitourinary

Prostatic Neoplasms

NCT03241537 2023-11-27

COHORT Trial in Clinical Pelivc Lymph Node Metastatic Prostate Cancer

Phase 3 Active not recruiting

61 enrolled

Genitourinary

Prostatic Neoplasms

NCT04136353 2023-07-28

DASL-HiCaP

Phase 3 Active not recruiting

1,100 enrolled

Genitourinary

Prostatic Neoplasms

NCT00430183 2023-02-09

Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

Phase 3 Active not recruiting

788 enrolled 10 charts

Genitourinary

Prostatic Neoplasms

Clinical Trials

RADVAN

PRIMORDIUM

PSMAddition

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

PRIMARY2

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

PSMAfore

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

CASPAR

SPARTAN

TITAN

CAPItello-281

PROTEUS

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

SPLASH

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

CONTACT-02

Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer

PEACE III

Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer

Prostate Cancer Diagnosis by Multiparametric Ultrasound (Wholemount)

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

CARLHA-2

KEYNOTE-641

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

CYCLONE 3

Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours

ENZARAD

PSMA SRT

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy

Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer

PATRON

Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis

[18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer

ENZAMET

PCS IV

CAPItello280

Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients

Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate

PEACE1

PEGASUS

MIP7

PACE

COHORT Trial in Clinical Pelivc Lymph Node Metastatic Prostate Cancer

DASL-HiCaP

Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer